常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-13.42/-4.18
|
|
企業價值
280.60M
|
| 資產負債 |
|
每股賬面淨值
5.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
441.00K
|
|
每股收益
0.94
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/15 21:09 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). |

15.11 
